Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gupta, S. R.
Right arrow Articles by Moritz, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gupta, S. R.
Right arrow Articles by Moritz, T.
NEUROLOGY 1995;45:2170-2173
© 1995 American Academy of Neurology

Bromocriptine treatment of nonfluent aphasia

Sudha R. Gupta, MD, Anthony G. Mlcoch, PhD, Celeste Scolaro, MS and Thomas Moritz, MS

From the Neurology Service (Dr. Gupta), Audiology and Speech Pathology Service (Dr. Mlcoch, and C. Scolaro), and Cooperative Studies Program Coordinating Center (T. Moritz), Edward Hines Jr. Veterans Affairs Hospital, Hines, IL.
Supported by a Veterans Affairs Biomedical Research Merit Review Grant.
Received January 24, 1995. Accepted in final form April 2, 1995.
Address correspondence and reprint requests to Dr. Sudha R. Gupta, Neurology Service (127), Edward Hines Jr. Veterans Affairs Hospital, Hines, IL 60141.

Using a double-blind, placebo-controlled, crossover design, we studied the effect of bromocriptine (15 mg daily) in 20 men with chronic nonfluent aphasia. The study was conducted over a 28-week period in two phases. In phase I, the patients received either bromocriptine or placebo; in phase II the treatments were crossed over. We evaluated each patient's language and nonverbal cognitive skills at the beginning and end of each phase and 6 weeks after completion of phase II. When compared with placebo treatment, bromocriptine did not significantly improve the patients' speech fluency, language content, overall degree of aphasia severity, or nonverbal cognitive abilities. Based on these results, bromocriptine is not recommended as monotherapy for the treatment of chronic nonfluent aphasia.

NEUROLOGY 1995;45: 2170-2173






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by AAN Enterprises, Inc.